dc.contributor.author | Tiu, C | |
dc.contributor.author | Shinde, R | |
dc.contributor.author | Yap, C | |
dc.contributor.author | Rao Baikady, B | |
dc.contributor.author | Banerji, U | |
dc.contributor.author | Minchom, AR | |
dc.contributor.author | de Bono, JS | |
dc.contributor.author | Lopez, JS | |
dc.date.accessioned | 2020-07-06T08:52:09Z | |
dc.date.issued | 2020-07-01 | |
dc.identifier.citation | The Lancet. Oncology, 2020, 21 (7), pp. 889 - 891 | |
dc.identifier.issn | 1470-2045 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3801 | |
dc.identifier.eissn | 1474-5488 | |
dc.identifier.doi | 10.1016/s1470-2045(20)30339-9 | |
dc.format | Print | |
dc.format.extent | 889 - 891 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE INC | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Pneumonia, Viral | |
dc.subject | Coronavirus Infections | |
dc.subject | Neoplasms | |
dc.subject | Antiviral Agents | |
dc.subject | Risk Assessment | |
dc.subject | Clinical Trials, Phase I as Topic | |
dc.subject | Pandemics | |
dc.subject | United Kingdom | |
dc.subject | Betacoronavirus | |
dc.subject | Data Management | |
dc.subject | COVID-19 | |
dc.subject | SARS-CoV-2 | |
dc.title | A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-05-27 | |
rioxxterms.versionofrecord | 10.1016/s1470-2045(20)30339-9 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2020-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | The Lancet. Oncology | |
pubs.issue | 7 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.publication-status | Published | |
pubs.volume | 21 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Medicine (de Bono Prostate) | |
icr.researchteam | Clinical Pharmacology – Adaptive Therapy | |
icr.researchteam | Clinical Trials & Statistics Unit | |
icr.researchteam | Prostate Cancer Targeted Therapy Group | |
dc.contributor.icrauthor | Tiu, Crescens | |
dc.contributor.icrauthor | Yap, Christina | |
dc.contributor.icrauthor | Banerji, Udai | |
dc.contributor.icrauthor | Minchom, Anna | |
dc.contributor.icrauthor | De Bono, Johann | |